Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 01/23 05:39:13 pm
71.18 EUR   +0.49%
01/23 SANOFI : Availability of the Pre-quarterly Results Communication
01/23 SANOFI : refund strengthens Dengvaxia case -- VACC
01/23 SANOFI : draws blood
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Signs Agreement with Principia Biopharma for MS Drug Candidate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 01:15pm CET

By Sonia Amaral Rohter

Sanofi SA (SAN.FR) on Thursday said that it has signed a license agreement with Principia Biopharma Inc. to develop an experimental oral treatment for multiple sclerosis, or MS, as part of its efforts to expand its MS franchise.

Under the terms of the deal, Sanofi will be granted an exclusive, worldwide license to develop and commercialize the drug, which is currently under clinical development. Sanofi will make an upfront payment of $40 million to Principia, and Principia will receive future milestone payments of up to $765 million as well as royalties on product sales.

According to the company, the drug candidate, referred to as PRN2246, shows promise in treating MS, a chronic inflammatory disorder of the central nervous system that affects over 2.5 million people worldwide. Principia has recently initiated a phase 1 trial of PRN2246 in healthy volunteers, according to the release.

Sanofi already has two MS medicines on the market, Aubagio and Lemtrada, as well as an in-house research and development program to address MS and other neurological diseases.

"Our agreement with Principia is an example of Sanofi's strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases," says Rita Balice-Gordon, global head of the company's MS/neuroscience therapeutic research area. "Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases."

The transaction, which is subject to customary regulatory approvals, is expected to close in the fourth quarter.

Write to Sonia Amaral Rohter at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:51a Two Biotech M&A’s Total $20 Billion, Ignites Hope for More Deals
01/23 SANOFI : Availability of the Pre-quarterly Results Communication
01/23 SANOFI : refund strengthens Dengvaxia case -- VACC
01/23 SANOFI : draws blood
01/23 SENATE PROBERS : P3.5-billion Dengvaxia deal rushed
01/23 SANOFI : to Acquire Bioverativ for $11.6 Billion
01/23 SANOFI : to buy Bioverativ for $11.6bn
01/23 Biotech indexes gain on deals
01/23 SANOFI : Ex-DOH chief Ona denies joining Aquino in Sanofi meeting
01/23 SANOFI : Gatchalian grills Garin on price talks with Sanofi in June 2015
More news
News from SeekingAlpha
01/23 Sanofi (SNY) To Acquire Bioverativ (BIVV) - Slideshow
01/23 Bioverativ's Shareholders Hit The Jackpot
01/23 YOUR DAILY PHARMA SCOOP : Omeros' OMS721, Celgene To Acquire Juno, BioCryst And ..
01/23 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 22, 2018
01/22 Biotech Forum Daily Digest For January 21st
Financials (€)
Sales 2017 35 679 M
EBIT 2017 9 098 M
Net income 2017 7 967 M
Debt 2017 5 761 M
Yield 2017 4,20%
P/E ratio 2017 11,20
P/E ratio 2018 15,57
EV / Sales 2017 2,67x
EV / Sales 2018 2,63x
Capitalization 89 468 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 83,8 €
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.42%109 634
JOHNSON & JOHNSON5.47%397 981
NOVARTIS1.29%226 840
PFIZER1.99%220 129
ROCHE HOLDING LTD.-4.34%211 542
MERCK AND COMPANY8.90%167 050